Aptose Biosciences Inc. - Common Shares

Historical Holders from Q4 2014 to Q1 2025

Type / Class
Equity / Common Shares
Shares outstanding
2,556,332
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aptose Biosciences Inc. - Common Shares based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Hanmi Pharmaceutical Co., Ltd. 20% $115,375 508,710 Hanmi Pharmaceutical Co., Ltd. 18 Mar 2025

Institutional Holders of Aptose Biosciences Inc. - Common Shares across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q1 0 $0 -$4,414 0
2024 Q4 19,592 $4,414 +$4,393 $0.2268 2
2024 Q3 92 $38 $0 $0.4130 1
2024 Q2 92 $70 -$43,999 $0.7609 1
2024 Q1 26,758 $44,153 -$79,200 $1.66 2
2023 Q4 74,758 $188,234 $0 $2.53 2
2023 Q3 74,758 $209,258 +$59,716 $2.80 2
2023 Q2 53,424 $247,427 -$16,350,655 $4.64 2
2023 Q1 20,956,721 $13,413,311 -$1,031,559 $0.6400 42
2022 Q4 22,969,085 $13,319,975 -$980,629 $0.5800 47
2022 Q3 24,503,339 $14,583,649 -$329,515 $0.5956 45
2022 Q2 25,037,246 $18,630,936 -$2,733,884 $0.7421 41
2022 Q1 28,520,122 $38,792,039 -$3,580,782 $1.36 50
2021 Q4 31,167,593 $42,354,178 -$20,836,313 $1.35 56
2021 Q3 39,573,391 $86,388,477 -$14,086,783 $2.18 61
2021 Q2 47,224,280 $156,736,746 -$38,362,555 $3.32 62
2021 Q1 52,368,071 $312,921,001 +$27,258,116 $5.98 70
2020 Q4 48,716,530 $213,595,767 -$10,656,459 $4.38 64
2020 Q3 46,405,416 $278,281,516 +$62,519,000 $6.00 62
2020 Q2 35,922,961 $226,532,098 +$4,418,986 $6.31 56
2020 Q1 34,645,396 $205,482,679 +$26,188,137 $5.94 49
2019 Q4 30,723,674 $174,218,000 +$81,216,820 $5.67 55
2019 Q3 14,205,904 $29,576,000 +$4,633,165 $2.08 30
2019 Q2 11,919,591 $31,117,000 +$22,569,720 $2.61 28
2019 Q1 3,293,470 $6,618,000 +$430,254 $2.00 20
2018 Q4 3,090,406 $5,904,000 +$3,412,187 $1.91 17
2018 Q3 1,070,513 $2,784,000 +$883,686 $2.60 14
2018 Q2 844,803 $3,282,000 +$1,473,043 $3.94 20
2018 Q1 477,823 $1,509,000 +$477,591 $3.17 14
2017 Q4 355,490 $795,000 +$420,131 $2.24 13
2017 Q3 168,847 $250,000 -$1,100,016 $1.48 9
2017 Q2 1,078,658 $1,327,000 -$1,369,552 $1.24 6
2017 Q1 2,425,471 $2,468,000 -$371,144 $1.03 9
2016 Q4 2,643,944 $3,621,000 -$280,205 $1.40 9
2016 Q3 2,899,922 $6,532,018 +$885,320 $2.25 10
2016 Q2 2,504,257 $6,161,020 -$322,239 $2.44 10
2016 Q1 2,628,108 $7,734,020 -$16,062 $2.95 12
2015 Q4 2,632,501 $6,764,012 -$502,487 $2.53 9
2015 Q3 2,751,269 $11,960,000 -$702,624 $4.31 12
2015 Q2 2,911,514 $14,907,000 -$54,104 $5.10 14
2015 Q1 2,921,962 $15,775,000 -$1,285,733 $5.42 13
2014 Q4 3,158,681 $18,681,000 +$18,658,021 $5.92 7